An offering of convertible promissory notes and Series C preferred stock warrants brought in an additional $6 million for Maple Grove, Minn.-based NxThera. The company, which makes the Rezum device for treating patients with benign prostate hyperplasia, still seeks to obtain $5.8 million in the offering to bring the total proceeds to $26.4 million.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.